PMC:7283670 / 66534-66792 JSONTXT

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T205","span":{"begin":4,"end":15},"obj":"Chemical"},{"id":"T206","span":{"begin":42,"end":44},"obj":"Chemical"}],"attributes":[{"id":"A205","pred":"chebi_id","subj":"T205","obj":"http://purl.obolibrary.org/obo/CHEBI_9513"},{"id":"A206","pred":"chebi_id","subj":"T206","obj":"http://purl.obolibrary.org/obo/CHEBI_74067"}],"text":"ys. thalidomide: 100 mg/d qn for 14 days II Primary (up to 28 days): time to clinical improvement\nSecondary (up to 28 days): clinical status (days 7, 14, 21, and 28), time to hospital discharge or NEWS2 (National Early Warning Score 2) of ≤2 maintained for"}

{"project":"LitCovid-sentences","denotations":[{"id":"T656","span":{"begin":17,"end":99},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"ys. thalidomide: 100 mg/d qn for 14 days II Primary (up to 28 days): time to clinical improvement\nSecondary (up to 28 days): clinical status (days 7, 14, 21, and 28), time to hospital discharge or NEWS2 (National Early Warning Score 2) of ≤2 maintained for"}